Crispr Therapeutics and StrideBio announced that a strategic collaboration, previously initiated in April 2017 to generate engineered AAV capsids with improved properties for in vivo gene editing programs, has now been expanded to include additional undisclosed applications. The financial terms of the new expanded development and option agreement have not been disclosed.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.